Description
OVERVIEWProduct overview
Ipamorelin is a pentapeptide secretagogue frequently studied because of its selectivity: in the published models it stimulates growth hormone release with comparatively little effect on cortisol or prolactin.
That selectivity makes it a common control or comparison arm in studies of the ghrelin receptor pathway.
All published work is preclinical or investigational. This material is supplied as a laboratory reference compound and is not authorised as a medicine in Ireland, the UK or the EU.
SUPPLY IN IRELANDIpamorelin Ireland — supplied to research laboratories
Research groups across Ireland buy Ipamorelin from Kensington Laboratories as a lyophilised Ipamorelin peptide, released only against a batch-matched certificate of analysis. Every vial of high purity Ipamorelin is verified by HPLC and LC-MS before it leaves the facility, so laboratories ordering Ipamorelin in Ireland receive material with documented purity and identity.
Laboratory Ipamorelin is packed for controlled storage and sent by tracked delivery in 3–5 days to Dublin, Cork, Galway, Limerick and the rest of Ireland. Delivery costs €9.90 per order. Teams planning Ipamorelin research can review the specifications, certificate of analysis and reference list on this page before ordering.
Institutions searching for Ipamorelin peptide suppliers in Ireland typically compare purity, batch documentation and delivery times. Each of those is published here: a 99% HPLC purity specification, a certificate matched to the batch code on your vial, and tracked delivery in 3–5 days.
Ipamorelin is supplied strictly for laboratory research use only. It is not a medicine and is not for human or veterinary consumption.
SPECIFICATIONSProduct specifications
- Purity: ≥ 99% (HPLC)
- Appearance: White lyophilised powder
- Quantity: 5 mg or 10 mg per vial
- CAS number: 170851-70-4
- Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH2
- Peptide class: Synthetic pentapeptide growth hormone secretagogue
- Also known as: NNC 26-0161, selective GH secretagogue
- Solubility: Soluble in bacteriostatic or sterile water
- Storage temperature: Store at 2–8°C; long-term −20°C, protected from light
- Shelf life: 24 months lyophilised; 30 days reconstituted at 2–8°C
- Manufacturing standard: ISO 9001 facility, GMP-aligned solid-phase synthesis
- Batch information: Batch number and expiry printed on every vial label
RESEARCHResearch overview
The following summary is provided for educational and scientific context only. It describes what has been observed in published laboratory and animal studies and does not represent established clinical outcomes, medical advice or a claim of efficacy in humans.
Background
Ipamorelin is a pentapeptide secretagogue frequently studied because of its selectivity: in the published models it stimulates growth hormone release with comparatively little effect on cortisol or prolactin.
That selectivity makes it a common control or comparison arm in studies of the ghrelin receptor pathway.
All published work is preclinical or investigational. This material is supplied as a laboratory reference compound and is not authorised as a medicine in Ireland, the UK or the EU.
Current research areas
Published investigation clusters around a small number of biological themes. Each remains experimental and none has been established as a therapeutic effect in humans.
- GHS-R1a receptor activation in pituitary preparations
- Selectivity profiling against cortisol and prolactin release
- Bone and connective tissue models
- Combined GHRH and secretagogue protocols
Scientific context and proposed mechanisms
Activity is attributed to agonism at the growth hormone secretagogue receptor GHS-R1a, the same receptor engaged by ghrelin, with the short sequence associated with a narrower endocrine response profile than GHRP-6.
Interpreting the evidence
Most published work in this area uses cell culture or rodent models with small group sizes and short observation windows. Independent replication varies considerably between compounds, and results are sensitive to species, route, dose and endpoint.
There is no regulatory-approved human protocol for this compound. Any laboratory protocol should be defined by the model under study, institutional ethical approval, appropriate controls and predefined endpoints.
References
CERTIFICATE OF ANALYSISIndependent batch testing
Every released batch is independently tested. Match the batch number on the vial to the certificate published online.
- Batch number
- KL-IPAMORELIN-2405A
- Testing laboratory
- Janoshik Analytical, s.r.o.
- Date tested
- 14 May 2026
- Reported purity
- 99.11%
- Method
- RP-HPLC with UV detection at 214 nm, confirmed by LC-MS
